Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 157 | 2024 | 17569 | 9.720 |
Why?
|
Uganda | 107 | 2024 | 1361 | 7.400 |
Why?
|
Anti-HIV Agents | 63 | 2024 | 4573 | 7.220 |
Why?
|
Rural Population | 56 | 2024 | 2325 | 6.120 |
Why?
|
South Africa | 53 | 2024 | 1873 | 3.160 |
Why?
|
Viral Load | 32 | 2024 | 3396 | 3.060 |
Why?
|
Anti-Retroviral Agents | 32 | 2024 | 1789 | 3.060 |
Why?
|
Drug Resistance, Viral | 14 | 2024 | 869 | 2.890 |
Why?
|
Antiretroviral Therapy, Highly Active | 20 | 2021 | 1903 | 2.800 |
Why?
|
Epidemics | 9 | 2024 | 517 | 2.160 |
Why?
|
Rural Health | 9 | 2021 | 302 | 1.960 |
Why?
|
CD4 Lymphocyte Count | 18 | 2022 | 2596 | 1.890 |
Why?
|
HIV-1 | 19 | 2024 | 6960 | 1.790 |
Why?
|
Malaria | 9 | 2022 | 1249 | 1.630 |
Why?
|
Oxazines | 7 | 2024 | 358 | 1.480 |
Why?
|
Africa South of the Sahara | 16 | 2023 | 752 | 1.450 |
Why?
|
Hypertension | 15 | 2024 | 8616 | 1.380 |
Why?
|
HIV Integrase Inhibitors | 7 | 2024 | 165 | 1.380 |
Why?
|
Carotid Artery Diseases | 5 | 2021 | 879 | 1.370 |
Why?
|
Heterocyclic Compounds, 3-Ring | 5 | 2024 | 296 | 1.310 |
Why?
|
Benzoxazines | 3 | 2021 | 320 | 1.250 |
Why?
|
Medication Adherence | 15 | 2022 | 2187 | 1.180 |
Why?
|
Communicable Disease Control | 5 | 2023 | 857 | 1.160 |
Why?
|
Humans | 268 | 2024 | 767991 | 1.150 |
Why?
|
Public Health | 8 | 2024 | 2679 | 1.140 |
Why?
|
Patient Compliance | 5 | 2017 | 2697 | 1.110 |
Why?
|
Adult | 137 | 2024 | 223583 | 1.090 |
Why?
|
Pyridones | 5 | 2024 | 819 | 1.090 |
Why?
|
Hemorrhagic Fever, Ebola | 5 | 2022 | 424 | 1.040 |
Why?
|
Viremia | 4 | 2022 | 726 | 1.040 |
Why?
|
Female | 175 | 2024 | 397113 | 1.030 |
Why?
|
Circumcision, Male | 4 | 2023 | 148 | 1.030 |
Why?
|
Male | 150 | 2024 | 364641 | 0.980 |
Why?
|
Virus Shedding | 2 | 2022 | 110 | 0.940 |
Why?
|
Transportation | 3 | 2015 | 217 | 0.920 |
Why?
|
Biomedical Technology | 2 | 2017 | 210 | 0.900 |
Why?
|
Acquired Immunodeficiency Syndrome | 5 | 2023 | 2204 | 0.880 |
Why?
|
Health Services Accessibility | 10 | 2021 | 5520 | 0.880 |
Why?
|
Prevalence | 29 | 2024 | 15867 | 0.880 |
Why?
|
Fibrin Fibrinogen Degradation Products | 4 | 2019 | 425 | 0.880 |
Why?
|
Cost-Benefit Analysis | 8 | 2023 | 5536 | 0.880 |
Why?
|
Blood Pressure | 8 | 2024 | 8540 | 0.880 |
Why?
|
Cardiovascular Diseases | 10 | 2024 | 15660 | 0.860 |
Why?
|
Cross-Sectional Studies | 41 | 2024 | 26375 | 0.860 |
Why?
|
Reagent Kits, Diagnostic | 4 | 2017 | 238 | 0.860 |
Why?
|
Diabetes Mellitus | 12 | 2024 | 5887 | 0.850 |
Why?
|
Bedding and Linens | 1 | 2023 | 41 | 0.830 |
Why?
|
Developing Countries | 4 | 2024 | 2913 | 0.830 |
Why?
|
HIV | 11 | 2023 | 1597 | 0.820 |
Why?
|
Disease Transmission, Infectious | 3 | 2020 | 560 | 0.800 |
Why?
|
Primary Health Care | 5 | 2021 | 4746 | 0.790 |
Why?
|
Drug Repositioning | 1 | 2024 | 246 | 0.790 |
Why?
|
Patient Acceptance of Health Care | 8 | 2019 | 3231 | 0.780 |
Why?
|
Middle Aged | 85 | 2024 | 223422 | 0.780 |
Why?
|
Piperazines | 6 | 2024 | 2552 | 0.780 |
Why?
|
Cohort Studies | 40 | 2024 | 41749 | 0.760 |
Why?
|
Quality of Life | 13 | 2024 | 13489 | 0.760 |
Why?
|
Proteinuria | 4 | 2008 | 612 | 0.750 |
Why?
|
Surgical Instruments | 2 | 2013 | 381 | 0.730 |
Why?
|
Interleukin-6 | 7 | 2021 | 3228 | 0.720 |
Why?
|
Opportunistic Infections | 1 | 2023 | 375 | 0.700 |
Why?
|
Public Sector | 2 | 2021 | 266 | 0.700 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 283 | 0.690 |
Why?
|
Fatty Acid-Binding Proteins | 2 | 2019 | 293 | 0.680 |
Why?
|
HIV Reverse Transcriptase | 1 | 2020 | 214 | 0.670 |
Why?
|
Diagnostic Tests, Routine | 6 | 2019 | 788 | 0.670 |
Why?
|
HIV Long-Term Survivors | 1 | 2020 | 140 | 0.650 |
Why?
|
Depression | 6 | 2024 | 8231 | 0.640 |
Why?
|
Microbial Sensitivity Tests | 7 | 2017 | 1967 | 0.640 |
Why?
|
Malaria, Falciparum | 5 | 2018 | 1077 | 0.630 |
Why?
|
Pregnancy Complications, Infectious | 7 | 2024 | 2185 | 0.620 |
Why?
|
Urban Health | 1 | 2021 | 534 | 0.620 |
Why?
|
Antigens, Protozoan | 2 | 2017 | 315 | 0.610 |
Why?
|
Health Status Disparities | 3 | 2020 | 1885 | 0.610 |
Why?
|
Government Programs | 2 | 2017 | 278 | 0.600 |
Why?
|
Staphylococcal Infections | 4 | 2021 | 1398 | 0.600 |
Why?
|
Young Adult | 41 | 2024 | 60048 | 0.600 |
Why?
|
Hypotension, Orthostatic | 1 | 2021 | 258 | 0.590 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 3 | 2019 | 704 | 0.590 |
Why?
|
Hospitals | 4 | 2021 | 3886 | 0.590 |
Why?
|
Decision Support Techniques | 3 | 2020 | 2008 | 0.590 |
Why?
|
Tuberculosis, Pulmonary | 3 | 2024 | 843 | 0.580 |
Why?
|
Parasitology | 1 | 2017 | 28 | 0.580 |
Why?
|
Neisseria gonorrhoeae | 3 | 2017 | 249 | 0.580 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 249 | 0.580 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2018 | 113 | 0.580 |
Why?
|
HIV Protease Inhibitors | 1 | 2020 | 430 | 0.570 |
Why?
|
Plasmodium falciparum | 6 | 2018 | 1741 | 0.570 |
Why?
|
Risk Factors | 30 | 2023 | 74936 | 0.560 |
Why?
|
Social Isolation | 1 | 2020 | 366 | 0.560 |
Why?
|
Tuberculosis | 8 | 2024 | 2029 | 0.560 |
Why?
|
Nevirapine | 1 | 2018 | 273 | 0.560 |
Why?
|
Dideoxynucleosides | 1 | 2017 | 135 | 0.560 |
Why?
|
Prosthesis-Related Infections | 2 | 2021 | 497 | 0.560 |
Why?
|
Life Expectancy | 3 | 2024 | 1248 | 0.550 |
Why?
|
Cephalosporins | 2 | 2017 | 200 | 0.550 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 252 | 0.550 |
Why?
|
Fasting | 2 | 2020 | 1609 | 0.550 |
Why?
|
Longitudinal Studies | 20 | 2023 | 14783 | 0.540 |
Why?
|
Posture | 1 | 2021 | 957 | 0.540 |
Why?
|
Mass Screening | 6 | 2021 | 5458 | 0.540 |
Why?
|
Glasgow Coma Scale | 1 | 2018 | 574 | 0.540 |
Why?
|
Metformin | 1 | 2024 | 909 | 0.540 |
Why?
|
Prospective Studies | 33 | 2024 | 54924 | 0.540 |
Why?
|
Polymerase Chain Reaction | 4 | 2019 | 6071 | 0.530 |
Why?
|
Diabetic Neuropathies | 1 | 2020 | 410 | 0.520 |
Why?
|
Gonorrhea | 3 | 2017 | 355 | 0.520 |
Why?
|
Respiration Disorders | 1 | 2019 | 364 | 0.520 |
Why?
|
Urine | 2 | 2008 | 362 | 0.510 |
Why?
|
Pandemics | 6 | 2023 | 8748 | 0.510 |
Why?
|
Models, Economic | 1 | 2020 | 719 | 0.500 |
Why?
|
Specialization | 1 | 2020 | 779 | 0.500 |
Why?
|
Inflammation | 8 | 2021 | 10871 | 0.490 |
Why?
|
Lupus Nephritis | 3 | 2007 | 327 | 0.490 |
Why?
|
Injections | 1 | 2018 | 840 | 0.490 |
Why?
|
Postpartum Hemorrhage | 2 | 2016 | 275 | 0.490 |
Why?
|
Blood Glucose | 4 | 2019 | 6429 | 0.480 |
Why?
|
Preventive Health Services | 1 | 2020 | 570 | 0.480 |
Why?
|
C-Reactive Protein | 4 | 2019 | 3858 | 0.470 |
Why?
|
Endocarditis, Bacterial | 1 | 2019 | 436 | 0.470 |
Why?
|
Aged | 46 | 2024 | 171446 | 0.470 |
Why?
|
Smoking Cessation | 3 | 2024 | 2085 | 0.470 |
Why?
|
Infectious Disease Transmission, Vertical | 4 | 2024 | 1354 | 0.460 |
Why?
|
Delayed-Action Preparations | 1 | 2018 | 968 | 0.460 |
Why?
|
Alkynes | 3 | 2021 | 326 | 0.460 |
Why?
|
Pneumonia, Viral | 3 | 2022 | 3238 | 0.460 |
Why?
|
Antimalarials | 4 | 2022 | 909 | 0.460 |
Why?
|
Ambulatory Care | 3 | 2021 | 2781 | 0.460 |
Why?
|
Enterobacter | 1 | 2014 | 44 | 0.460 |
Why?
|
Medically Underserved Area | 1 | 2016 | 268 | 0.450 |
Why?
|
Long QT Syndrome | 1 | 2018 | 472 | 0.450 |
Why?
|
Drug Resistance, Bacterial | 4 | 2015 | 1063 | 0.450 |
Why?
|
Geographic Information Systems | 2 | 2013 | 283 | 0.450 |
Why?
|
Cyclopropanes | 3 | 2021 | 436 | 0.450 |
Why?
|
Virus Replication | 1 | 2022 | 2458 | 0.440 |
Why?
|
Chemoprevention | 3 | 2022 | 327 | 0.440 |
Why?
|
Hematoma | 1 | 2018 | 766 | 0.440 |
Why?
|
Adolescent | 35 | 2024 | 89155 | 0.440 |
Why?
|
Soil | 1 | 2014 | 120 | 0.440 |
Why?
|
Helminthiasis | 1 | 2014 | 81 | 0.440 |
Why?
|
Ambulatory Care Facilities | 6 | 2020 | 939 | 0.440 |
Why?
|
Reagent Strips | 2 | 2017 | 40 | 0.440 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 3251 | 0.430 |
Why?
|
Hemoglobins | 2 | 2017 | 1531 | 0.430 |
Why?
|
Sex Factors | 9 | 2021 | 10627 | 0.430 |
Why?
|
Dangerous Behavior | 1 | 2013 | 65 | 0.430 |
Why?
|
Climate Change | 2 | 2017 | 509 | 0.430 |
Why?
|
Risk Assessment | 11 | 2021 | 24314 | 0.430 |
Why?
|
Stereotyping | 1 | 2015 | 241 | 0.430 |
Why?
|
Antigens, CD | 3 | 2018 | 4035 | 0.420 |
Why?
|
Stroke | 5 | 2024 | 9755 | 0.420 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2018 | 621 | 0.420 |
Why?
|
Referral and Consultation | 5 | 2021 | 3619 | 0.420 |
Why?
|
Carbapenems | 1 | 2014 | 125 | 0.420 |
Why?
|
Health Resources | 3 | 2017 | 950 | 0.420 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3115 | 0.410 |
Why?
|
Rural Health Services | 5 | 2018 | 394 | 0.410 |
Why?
|
Data Collection | 3 | 2020 | 3326 | 0.400 |
Why?
|
Spirometry | 4 | 2022 | 929 | 0.400 |
Why?
|
HIV Seropositivity | 2 | 2021 | 966 | 0.400 |
Why?
|
Plasmodium | 1 | 2015 | 248 | 0.400 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2819 | 0.400 |
Why?
|
Body Mass Index | 6 | 2023 | 13053 | 0.390 |
Why?
|
Bacteremia | 2 | 2021 | 986 | 0.390 |
Why?
|
Enterobacteriaceae Infections | 1 | 2014 | 190 | 0.390 |
Why?
|
Telemedicine | 4 | 2017 | 3109 | 0.390 |
Why?
|
Loneliness | 2 | 2024 | 211 | 0.380 |
Why?
|
Ritonavir | 2 | 2023 | 331 | 0.370 |
Why?
|
Telemetry | 1 | 2012 | 200 | 0.370 |
Why?
|
Electrocardiography | 3 | 2019 | 6411 | 0.370 |
Why?
|
HIV Seronegativity | 3 | 2021 | 210 | 0.370 |
Why?
|
Population Surveillance | 2 | 2018 | 2594 | 0.360 |
Why?
|
Weight Gain | 5 | 2024 | 2359 | 0.360 |
Why?
|
Disclosure | 2 | 2017 | 755 | 0.360 |
Why?
|
Aging | 5 | 2024 | 8744 | 0.360 |
Why?
|
Cholesterol, LDL | 1 | 2020 | 2403 | 0.360 |
Why?
|
Sensitivity and Specificity | 14 | 2022 | 14718 | 0.350 |
Why?
|
Syphilis Serodiagnosis | 2 | 2014 | 37 | 0.350 |
Why?
|
Women | 1 | 2012 | 225 | 0.350 |
Why?
|
Mouth Diseases | 2 | 2023 | 239 | 0.350 |
Why?
|
Heart Valve Prosthesis | 1 | 2019 | 1468 | 0.350 |
Why?
|
World Health Organization | 4 | 2023 | 1328 | 0.340 |
Why?
|
Obesity | 7 | 2024 | 13091 | 0.340 |
Why?
|
Residence Characteristics | 3 | 2020 | 2118 | 0.340 |
Why?
|
Cause of Death | 1 | 2020 | 3720 | 0.340 |
Why?
|
HIV Integrase | 2 | 2021 | 122 | 0.340 |
Why?
|
Liberia | 6 | 2024 | 176 | 0.330 |
Why?
|
Reimbursement Mechanisms | 1 | 2015 | 670 | 0.330 |
Why?
|
Treatment Failure | 5 | 2022 | 2660 | 0.330 |
Why?
|
Women's Health | 1 | 2019 | 2082 | 0.330 |
Why?
|
Anti-Bacterial Agents | 6 | 2019 | 7470 | 0.320 |
Why?
|
Counseling | 3 | 2019 | 1554 | 0.320 |
Why?
|
Sexual Partners | 2 | 2020 | 805 | 0.320 |
Why?
|
Placenta Diseases | 2 | 2021 | 199 | 0.310 |
Why?
|
Dental Caries | 2 | 2023 | 429 | 0.310 |
Why?
|
Time Factors | 12 | 2022 | 40214 | 0.310 |
Why?
|
Emergencies | 1 | 2015 | 1224 | 0.300 |
Why?
|
Urinalysis | 2 | 2007 | 370 | 0.300 |
Why?
|
Anemia | 1 | 2017 | 1514 | 0.300 |
Why?
|
Sexual Behavior | 3 | 2024 | 2197 | 0.300 |
Why?
|
Lamivudine | 3 | 2024 | 367 | 0.300 |
Why?
|
Pregnancy | 24 | 2024 | 30260 | 0.290 |
Why?
|
Suicidal Ideation | 1 | 2018 | 1467 | 0.290 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2024 | 620 | 0.290 |
Why?
|
Lymphogranuloma Venereum | 1 | 2007 | 14 | 0.290 |
Why?
|
Syphilis | 2 | 2014 | 243 | 0.290 |
Why?
|
Odds Ratio | 8 | 2018 | 9666 | 0.290 |
Why?
|
Mycobacterium tuberculosis | 6 | 2022 | 1930 | 0.290 |
Why?
|
Blood Pressure Determination | 2 | 2023 | 646 | 0.290 |
Why?
|
Forced Expiratory Volume | 4 | 2022 | 1831 | 0.280 |
Why?
|
Lung | 3 | 2024 | 10094 | 0.280 |
Why?
|
Cerebral Hemorrhage | 1 | 2018 | 2655 | 0.280 |
Why?
|
Heart Rate | 1 | 2018 | 4215 | 0.280 |
Why?
|
Quality Assurance, Health Care | 1 | 2017 | 2175 | 0.280 |
Why?
|
Case-Control Studies | 8 | 2022 | 22287 | 0.280 |
Why?
|
Carotid Arteries | 3 | 2022 | 942 | 0.270 |
Why?
|
Clinical Laboratory Techniques | 1 | 2012 | 746 | 0.270 |
Why?
|
Treatment Outcome | 17 | 2024 | 65364 | 0.270 |
Why?
|
Child, Preschool | 15 | 2024 | 42665 | 0.270 |
Why?
|
Heart Diseases | 1 | 2019 | 2819 | 0.270 |
Why?
|
Atherosclerosis | 3 | 2022 | 3433 | 0.260 |
Why?
|
Community Health Services | 3 | 2021 | 659 | 0.260 |
Why?
|
Comorbidity | 6 | 2021 | 10590 | 0.260 |
Why?
|
Malnutrition | 1 | 2012 | 632 | 0.250 |
Why?
|
Child | 22 | 2024 | 80906 | 0.250 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2020 | 12252 | 0.250 |
Why?
|
Biological Specimen Banks | 2 | 2022 | 788 | 0.250 |
Why?
|
Chlamydia trachomatis | 1 | 2007 | 239 | 0.250 |
Why?
|
Antiviral Agents | 3 | 2024 | 3073 | 0.240 |
Why?
|
Myocardial Infarction | 3 | 2024 | 11519 | 0.240 |
Why?
|
Alanine | 2 | 2024 | 614 | 0.240 |
Why?
|
Interpersonal Relations | 1 | 2012 | 1434 | 0.240 |
Why?
|
Infant | 14 | 2022 | 36534 | 0.240 |
Why?
|
Fluoroquinolones | 1 | 2007 | 309 | 0.240 |
Why?
|
Incidence | 13 | 2024 | 21532 | 0.240 |
Why?
|
Protozoan Proteins | 3 | 2017 | 843 | 0.240 |
Why?
|
Social Stigma | 4 | 2022 | 788 | 0.230 |
Why?
|
Disease Management | 4 | 2019 | 2533 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10396 | 0.230 |
Why?
|
Unsafe Sex | 2 | 2018 | 239 | 0.230 |
Why?
|
Quinolones | 1 | 2008 | 389 | 0.230 |
Why?
|
Prenatal Care | 2 | 2022 | 1162 | 0.220 |
Why?
|
Coronary Artery Disease | 2 | 2022 | 6569 | 0.220 |
Why?
|
RNA, Viral | 3 | 2017 | 2871 | 0.220 |
Why?
|
Age Factors | 5 | 2021 | 18407 | 0.220 |
Why?
|
Hypothermia | 2 | 2022 | 189 | 0.220 |
Why?
|
Infant, Newborn | 10 | 2023 | 26420 | 0.210 |
Why?
|
Adenosine Monophosphate | 1 | 2024 | 232 | 0.210 |
Why?
|
Monkeypox virus | 1 | 2023 | 43 | 0.210 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2008 | 618 | 0.210 |
Why?
|
Activities of Daily Living | 2 | 2022 | 2429 | 0.200 |
Why?
|
Sex Distribution | 2 | 2019 | 2276 | 0.200 |
Why?
|
Artemisinins | 2 | 2022 | 217 | 0.200 |
Why?
|
Virus Cultivation | 1 | 2022 | 88 | 0.200 |
Why?
|
Respiratory Syncytial Virus Vaccines | 1 | 2022 | 37 | 0.200 |
Why?
|
Physicians | 1 | 2020 | 4598 | 0.200 |
Why?
|
Mortality | 3 | 2020 | 2910 | 0.200 |
Why?
|
Postpartum Period | 3 | 2018 | 1198 | 0.190 |
Why?
|
Antitubercular Agents | 5 | 2015 | 1397 | 0.190 |
Why?
|
Critical Care | 1 | 2014 | 2715 | 0.190 |
Why?
|
Health Services Needs and Demand | 2 | 2021 | 1406 | 0.190 |
Why?
|
Basic Reproduction Number | 1 | 2021 | 38 | 0.190 |
Why?
|
Quinolines | 2 | 2024 | 770 | 0.190 |
Why?
|
Cholesterol, HDL | 2 | 2020 | 1820 | 0.190 |
Why?
|
Treponema pallidum | 2 | 2014 | 48 | 0.190 |
Why?
|
Insecticide-Treated Bednets | 1 | 2022 | 70 | 0.190 |
Why?
|
SAIDS Vaccines | 1 | 2022 | 144 | 0.190 |
Why?
|
District of Columbia | 1 | 2021 | 159 | 0.190 |
Why?
|
Point-of-Care Systems | 3 | 2023 | 1238 | 0.190 |
Why?
|
Fever | 5 | 2022 | 1613 | 0.180 |
Why?
|
Colony Count, Microbial | 2 | 2019 | 328 | 0.180 |
Why?
|
Africa | 3 | 2021 | 725 | 0.180 |
Why?
|
Staphylococcus aureus | 2 | 2021 | 1430 | 0.180 |
Why?
|
Health Communication | 1 | 2014 | 216 | 0.180 |
Why?
|
Review Literature as Topic | 1 | 2023 | 297 | 0.180 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7445 | 0.180 |
Why?
|
Phylogeny | 3 | 2024 | 2843 | 0.180 |
Why?
|
Meta-Analysis as Topic | 2 | 2023 | 1363 | 0.180 |
Why?
|
Rheumatology | 1 | 2007 | 617 | 0.180 |
Why?
|
Lung Diseases, Obstructive | 1 | 2022 | 311 | 0.180 |
Why?
|
Placenta | 4 | 2023 | 1725 | 0.180 |
Why?
|
Infection Control | 2 | 2020 | 985 | 0.180 |
Why?
|
Aneurysm, Infected | 1 | 2021 | 81 | 0.180 |
Why?
|
Drug Resistance | 3 | 2022 | 1598 | 0.180 |
Why?
|
Crowding | 1 | 2021 | 144 | 0.170 |
Why?
|
Child, Hospitalized | 1 | 2022 | 182 | 0.170 |
Why?
|
Vital Capacity | 2 | 2022 | 996 | 0.170 |
Why?
|
Insecticides | 1 | 2022 | 200 | 0.170 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2022 | 4415 | 0.170 |
Why?
|
Health Behavior | 2 | 2021 | 2650 | 0.170 |
Why?
|
Disease Outbreaks | 3 | 2022 | 1761 | 0.170 |
Why?
|
HIV Seroprevalence | 1 | 2019 | 89 | 0.160 |
Why?
|
Prisons | 1 | 2021 | 178 | 0.160 |
Why?
|
Prognosis | 6 | 2020 | 29979 | 0.160 |
Why?
|
Atrial Fibrillation | 1 | 2018 | 5182 | 0.160 |
Why?
|
Myocardial Reperfusion | 1 | 2020 | 339 | 0.160 |
Why?
|
Lentivirus | 1 | 2022 | 518 | 0.160 |
Why?
|
Parasitemia | 2 | 2017 | 166 | 0.160 |
Why?
|
Early Diagnosis | 2 | 2019 | 1193 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 219 | 0.160 |
Why?
|
Infant Mortality | 1 | 2024 | 752 | 0.160 |
Why?
|
Hospitalization | 5 | 2021 | 10840 | 0.160 |
Why?
|
Nasal Cavity | 2 | 2019 | 310 | 0.150 |
Why?
|
Retrospective Studies | 14 | 2024 | 81746 | 0.150 |
Why?
|
Demography | 2 | 2021 | 1641 | 0.150 |
Why?
|
Puerperal Infection | 1 | 2018 | 46 | 0.150 |
Why?
|
Travel | 2 | 2015 | 805 | 0.150 |
Why?
|
Africa, Western | 2 | 2015 | 160 | 0.150 |
Why?
|
Health Policy | 2 | 2015 | 2698 | 0.150 |
Why?
|
Microscopy | 2 | 2017 | 909 | 0.150 |
Why?
|
Epidemiologic Factors | 1 | 2017 | 36 | 0.150 |
Why?
|
Radiography, Thoracic | 1 | 2024 | 1321 | 0.140 |
Why?
|
Informed Consent | 2 | 2022 | 1010 | 0.140 |
Why?
|
Maternal Mortality | 2 | 2018 | 310 | 0.140 |
Why?
|
Limit of Detection | 1 | 2018 | 277 | 0.140 |
Why?
|
Interviews as Topic | 2 | 2017 | 2741 | 0.140 |
Why?
|
Respiratory Function Tests | 2 | 2022 | 1695 | 0.140 |
Why?
|
Self Report | 2 | 2019 | 3773 | 0.140 |
Why?
|
Family Planning Services | 1 | 2020 | 279 | 0.140 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11930 | 0.140 |
Why?
|
Poisson Distribution | 1 | 2018 | 506 | 0.140 |
Why?
|
Hepatitis B Vaccines | 1 | 2018 | 178 | 0.140 |
Why?
|
Acinetobacter | 1 | 2017 | 39 | 0.140 |
Why?
|
Mutation | 8 | 2024 | 30211 | 0.140 |
Why?
|
Xanthenes | 2 | 2014 | 71 | 0.140 |
Why?
|
Carrier State | 2 | 2019 | 529 | 0.140 |
Why?
|
Public Policy | 1 | 2021 | 552 | 0.140 |
Why?
|
Diarrhea | 3 | 2018 | 1320 | 0.140 |
Why?
|
Burkina Faso | 3 | 2021 | 88 | 0.140 |
Why?
|
Acinetobacter Infections | 1 | 2017 | 73 | 0.140 |
Why?
|
Lost to Follow-Up | 1 | 2017 | 124 | 0.130 |
Why?
|
Colorimetry | 2 | 2014 | 151 | 0.130 |
Why?
|
Syndrome | 1 | 2023 | 3271 | 0.130 |
Why?
|
Computer Simulation | 4 | 2024 | 6283 | 0.130 |
Why?
|
Papillomavirus Vaccines | 1 | 2022 | 497 | 0.130 |
Why?
|
Blood Chemical Analysis | 1 | 2018 | 435 | 0.130 |
Why?
|
Multivariate Analysis | 4 | 2018 | 12075 | 0.130 |
Why?
|
AIDS Vaccines | 1 | 2022 | 900 | 0.130 |
Why?
|
HLA-B Antigens | 1 | 2017 | 330 | 0.130 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2022 | 617 | 0.130 |
Why?
|
Life Style | 2 | 2019 | 3932 | 0.130 |
Why?
|
Vitamin K Deficiency Bleeding | 1 | 2015 | 9 | 0.130 |
Why?
|
Blood Vessel Prosthesis | 1 | 2021 | 956 | 0.130 |
Why?
|
Vaccination | 3 | 2022 | 3437 | 0.130 |
Why?
|
Aged, 80 and over | 9 | 2021 | 59598 | 0.130 |
Why?
|
Carbon Monoxide | 1 | 2019 | 560 | 0.130 |
Why?
|
Housing | 1 | 2020 | 683 | 0.130 |
Why?
|
Asymptomatic Diseases | 1 | 2019 | 590 | 0.130 |
Why?
|
Climate | 1 | 2016 | 146 | 0.130 |
Why?
|
Communicable Diseases | 1 | 2024 | 874 | 0.120 |
Why?
|
Quality Improvement | 2 | 2021 | 3855 | 0.120 |
Why?
|
Professional Role | 1 | 2018 | 315 | 0.120 |
Why?
|
Macrophage Activation | 1 | 2018 | 557 | 0.120 |
Why?
|
Cytokines | 2 | 2024 | 7450 | 0.120 |
Why?
|
Antibodies, Viral | 4 | 2023 | 3216 | 0.120 |
Why?
|
Ciprofloxacin | 1 | 2017 | 313 | 0.120 |
Why?
|
Weather | 1 | 2016 | 234 | 0.120 |
Why?
|
Influenza Vaccines | 1 | 2022 | 780 | 0.120 |
Why?
|
Meningitis, Bacterial | 1 | 2017 | 225 | 0.120 |
Why?
|
Philosophy, Medical | 1 | 2015 | 78 | 0.120 |
Why?
|
Biostatistics | 1 | 2016 | 163 | 0.120 |
Why?
|
Drug Synergism | 1 | 2019 | 1760 | 0.120 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2017 | 591 | 0.120 |
Why?
|
Program Evaluation | 3 | 2018 | 2506 | 0.120 |
Why?
|
Serum Albumin | 1 | 2018 | 677 | 0.120 |
Why?
|
Peru | 2 | 2008 | 890 | 0.120 |
Why?
|
Ebolavirus | 1 | 2017 | 250 | 0.120 |
Why?
|
Survival Analysis | 2 | 2019 | 10098 | 0.110 |
Why?
|
Prenatal Nutritional Physiological Phenomena | 1 | 2015 | 161 | 0.110 |
Why?
|
Oxytocics | 1 | 2014 | 67 | 0.110 |
Why?
|
Reproducibility of Results | 4 | 2022 | 20218 | 0.110 |
Why?
|
Qualitative Research | 2 | 2022 | 3140 | 0.110 |
Why?
|
Respiratory Tract Diseases | 1 | 2019 | 744 | 0.110 |
Why?
|
Cryptococcus | 1 | 2013 | 28 | 0.110 |
Why?
|
Publishing | 1 | 2021 | 837 | 0.110 |
Why?
|
Misoprostol | 1 | 2014 | 94 | 0.110 |
Why?
|
Blood Bactericidal Activity | 1 | 2013 | 124 | 0.110 |
Why?
|
Bioethics | 1 | 2015 | 118 | 0.110 |
Why?
|
Regression Analysis | 3 | 2018 | 6339 | 0.110 |
Why?
|
Genotype | 2 | 2018 | 13042 | 0.110 |
Why?
|
Vascular Diseases | 1 | 2021 | 1162 | 0.110 |
Why?
|
Confidentiality | 1 | 2017 | 607 | 0.110 |
Why?
|
Leukocyte Count | 1 | 2017 | 1609 | 0.110 |
Why?
|
AIDS Serodiagnosis | 1 | 2014 | 220 | 0.110 |
Why?
|
Radiography | 1 | 2024 | 6983 | 0.110 |
Why?
|
Meningitis, Cryptococcal | 1 | 2013 | 67 | 0.110 |
Why?
|
DMF Index | 2 | 2023 | 87 | 0.110 |
Why?
|
Vitamin K | 1 | 2015 | 314 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2568 | 0.110 |
Why?
|
Risk-Taking | 1 | 2018 | 1023 | 0.100 |
Why?
|
Mycobacterium bovis | 1 | 2013 | 148 | 0.100 |
Why?
|
Recombination, Genetic | 1 | 2017 | 1525 | 0.100 |
Why?
|
Immunity, Innate | 2 | 2016 | 3079 | 0.100 |
Why?
|
Hepatitis B | 1 | 2018 | 711 | 0.100 |
Why?
|
Massachusetts | 2 | 2023 | 8888 | 0.100 |
Why?
|
Fibrosis | 1 | 2020 | 2080 | 0.100 |
Why?
|
Bacteria | 3 | 2024 | 2216 | 0.100 |
Why?
|
Maternal Health Services | 2 | 2016 | 472 | 0.100 |
Why?
|
Chromatography, Affinity | 1 | 2013 | 525 | 0.100 |
Why?
|
Altitude | 1 | 2013 | 163 | 0.100 |
Why?
|
Triglycerides | 1 | 2020 | 2463 | 0.100 |
Why?
|
Income | 1 | 2021 | 1878 | 0.100 |
Why?
|
DNA Gyrase | 2 | 2017 | 86 | 0.100 |
Why?
|
Viruses | 1 | 2016 | 373 | 0.100 |
Why?
|
Lung Diseases | 1 | 2022 | 1944 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2448 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1512 | 0.100 |
Why?
|
Monocytes | 1 | 2021 | 2605 | 0.100 |
Why?
|
ROC Curve | 1 | 2019 | 3628 | 0.100 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3108 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 6314 | 0.090 |
Why?
|
Thrombolytic Therapy | 1 | 2020 | 2055 | 0.090 |
Why?
|
Research Design | 2 | 2017 | 6211 | 0.090 |
Why?
|
Protein Precursors | 1 | 2015 | 1134 | 0.090 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2021 | 1250 | 0.090 |
Why?
|
Labor, Obstetric | 1 | 2014 | 323 | 0.090 |
Why?
|
Patient Admission | 1 | 2018 | 1365 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1209 | 0.090 |
Why?
|
Malaria, Vivax | 1 | 2013 | 168 | 0.090 |
Why?
|
Spouse Abuse | 1 | 2012 | 181 | 0.090 |
Why?
|
Blood | 1 | 2013 | 599 | 0.090 |
Why?
|
Cerebrospinal Fluid | 1 | 2013 | 540 | 0.090 |
Why?
|
Oxytocin | 1 | 2014 | 404 | 0.090 |
Why?
|
Biological Assay | 1 | 2013 | 627 | 0.090 |
Why?
|
Hospital Mortality | 2 | 2022 | 5349 | 0.090 |
Why?
|
Biomedical Research | 2 | 2015 | 3463 | 0.090 |
Why?
|
Lipids | 2 | 2019 | 3342 | 0.090 |
Why?
|
Plaque, Atherosclerotic | 1 | 2021 | 1551 | 0.090 |
Why?
|
Health Facilities | 1 | 2015 | 578 | 0.090 |
Why?
|
Age Distribution | 1 | 2015 | 2871 | 0.080 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1422 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1640 | 0.080 |
Why?
|
Pregnancy Outcome | 1 | 2020 | 2972 | 0.080 |
Why?
|
Carotid Artery, Common | 1 | 2010 | 174 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2021 | 2043 | 0.080 |
Why?
|
Anxiety | 1 | 2024 | 4672 | 0.080 |
Why?
|
Urban Population | 2 | 2008 | 2045 | 0.080 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 277 | 0.080 |
Why?
|
Leukocytes | 1 | 2017 | 2035 | 0.080 |
Why?
|
Delivery, Obstetric | 1 | 2016 | 954 | 0.080 |
Why?
|
Antigens, Bacterial | 1 | 2014 | 1150 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 3669 | 0.080 |
Why?
|
Breast Feeding | 1 | 2017 | 1363 | 0.080 |
Why?
|
Receptors, IgG | 2 | 2022 | 564 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39345 | 0.080 |
Why?
|
Health Personnel | 2 | 2022 | 3385 | 0.080 |
Why?
|
Length of Stay | 2 | 2022 | 6495 | 0.080 |
Why?
|
Sleep | 1 | 2024 | 4817 | 0.080 |
Why?
|
Ultrasonography | 2 | 2020 | 6004 | 0.080 |
Why?
|
Tuberculosis, Pleural | 1 | 2008 | 14 | 0.080 |
Why?
|
Pilot Projects | 2 | 2022 | 8740 | 0.080 |
Why?
|
United States | 6 | 2023 | 73027 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2017 | 5366 | 0.070 |
Why?
|
Poverty | 1 | 2020 | 2720 | 0.070 |
Why?
|
Plasmodium berghei | 1 | 2008 | 161 | 0.070 |
Why?
|
Nutritional Status | 2 | 2015 | 1628 | 0.070 |
Why?
|
Prenatal Diagnosis | 1 | 2015 | 1275 | 0.070 |
Why?
|
Health Care Costs | 1 | 2020 | 3239 | 0.070 |
Why?
|
Logistic Models | 4 | 2018 | 13289 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5505 | 0.070 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 2029 | 0.070 |
Why?
|
Myocardium | 1 | 2020 | 4788 | 0.070 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 714 | 0.070 |
Why?
|
Laboratories | 1 | 2010 | 463 | 0.070 |
Why?
|
Health Status | 1 | 2020 | 4092 | 0.070 |
Why?
|
Health Literacy | 1 | 2012 | 466 | 0.070 |
Why?
|
Phenotype | 2 | 2021 | 16723 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2018 | 4055 | 0.070 |
Why?
|
Pneumonia | 1 | 2018 | 2163 | 0.070 |
Why?
|
Lower Extremity | 1 | 2014 | 1216 | 0.060 |
Why?
|
Exercise | 1 | 2023 | 5955 | 0.060 |
Why?
|
Azithromycin | 1 | 2007 | 201 | 0.060 |
Why?
|
Pregnant Women | 2 | 2022 | 576 | 0.060 |
Why?
|
Linear Models | 1 | 2016 | 5884 | 0.060 |
Why?
|
DNA, Bacterial | 2 | 2007 | 1478 | 0.060 |
Why?
|
Language | 1 | 2015 | 1558 | 0.060 |
Why?
|
Pediatrics | 1 | 2020 | 3629 | 0.060 |
Why?
|
Insulin Resistance | 1 | 2019 | 3986 | 0.060 |
Why?
|
Health Promotion | 1 | 2017 | 2210 | 0.060 |
Why?
|
Sentinel Surveillance | 1 | 2007 | 292 | 0.060 |
Why?
|
Risk | 1 | 2017 | 9609 | 0.060 |
Why?
|
Sputum | 2 | 2022 | 516 | 0.060 |
Why?
|
Hemagglutination Tests | 1 | 2004 | 76 | 0.060 |
Why?
|
Predictive Value of Tests | 5 | 2021 | 15442 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8052 | 0.060 |
Why?
|
Urethra | 1 | 2007 | 406 | 0.060 |
Why?
|
Patient Preference | 1 | 2012 | 946 | 0.060 |
Why?
|
San Francisco | 1 | 2004 | 166 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9493 | 0.060 |
Why?
|
Environmental Exposure | 1 | 2019 | 4543 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4648 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8377 | 0.060 |
Why?
|
Chronic Disease | 1 | 2019 | 9384 | 0.060 |
Why?
|
Smoking | 2 | 2022 | 9089 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3414 | 0.060 |
Why?
|
Disease Progression | 1 | 2021 | 13665 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12536 | 0.050 |
Why?
|
Homosexuality, Male | 2 | 2024 | 1344 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2019 | 15944 | 0.050 |
Why?
|
Antibodies, Neutralizing | 2 | 2023 | 2011 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2018 | 4310 | 0.050 |
Why?
|
Peripheral Arterial Disease | 1 | 2014 | 1304 | 0.050 |
Why?
|
Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2022 | 52 | 0.050 |
Why?
|
Permethrin | 1 | 2022 | 16 | 0.050 |
Why?
|
Convalescence | 1 | 2022 | 107 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1743 | 0.050 |
Why?
|
Wound Healing | 1 | 2013 | 2808 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2022 | 188 | 0.050 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2022 | 71 | 0.050 |
Why?
|
Floods | 1 | 2022 | 42 | 0.050 |
Why?
|
Proteins | 1 | 2017 | 6009 | 0.050 |
Why?
|
Child Mortality | 1 | 2024 | 204 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2015 | 2972 | 0.050 |
Why?
|
Creatinine | 1 | 2007 | 1918 | 0.050 |
Why?
|
Vero Cells | 1 | 2022 | 486 | 0.050 |
Why?
|
Drug Substitution | 1 | 2024 | 291 | 0.050 |
Why?
|
Mosquito Control | 1 | 2022 | 110 | 0.050 |
Why?
|
Hodgkin Disease | 1 | 2009 | 1383 | 0.050 |
Why?
|
Neutralization Tests | 1 | 2022 | 739 | 0.040 |
Why?
|
Integrases | 1 | 2023 | 520 | 0.040 |
Why?
|
Postnatal Care | 1 | 2022 | 273 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2024 | 13499 | 0.040 |
Why?
|
Models, Statistical | 1 | 2014 | 5107 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2021 | 472 | 0.040 |
Why?
|
Respiratory Tract Infections | 2 | 2018 | 1014 | 0.040 |
Why?
|
Drug Monitoring | 2 | 2016 | 964 | 0.040 |
Why?
|
BCG Vaccine | 1 | 2022 | 381 | 0.040 |
Why?
|
Parity | 1 | 2022 | 931 | 0.040 |
Why?
|
Case Management | 1 | 2021 | 277 | 0.040 |
Why?
|
Sepsis | 1 | 2013 | 2608 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2021 | 468 | 0.040 |
Why?
|
Culture Media | 2 | 2013 | 898 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3269 | 0.040 |
Why?
|
Information Systems | 1 | 2021 | 400 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 16041 | 0.040 |
Why?
|
Cameroon | 1 | 2018 | 79 | 0.040 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2022 | 418 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2021 | 652 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2012 | 7851 | 0.040 |
Why?
|
Aorta, Abdominal | 1 | 2021 | 627 | 0.040 |
Why?
|
Coitus | 1 | 2019 | 132 | 0.040 |
Why?
|
DNA, Protozoan | 1 | 2018 | 227 | 0.040 |
Why?
|
Fetal Growth Retardation | 1 | 2021 | 592 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2007 | 2592 | 0.040 |
Why?
|
Stillbirth | 1 | 2020 | 381 | 0.040 |
Why?
|
RNA, Ribosomal, 18S | 1 | 2017 | 54 | 0.040 |
Why?
|
Fetal Blood | 1 | 2024 | 1361 | 0.040 |
Why?
|
Carboxylic Ester Hydrolases | 1 | 2017 | 99 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2022 | 4564 | 0.030 |
Why?
|
Vasculitis | 1 | 2021 | 525 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2022 | 1082 | 0.030 |
Why?
|
Cell Movement | 1 | 2009 | 5209 | 0.030 |
Why?
|
Oral Health | 1 | 2022 | 493 | 0.030 |
Why?
|
HIV Enteropathy | 1 | 2016 | 4 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2022 | 1478 | 0.030 |
Why?
|
Substance Abuse, Intravenous | 1 | 2021 | 530 | 0.030 |
Why?
|
Aftercare | 1 | 2022 | 916 | 0.030 |
Why?
|
Heart Failure | 2 | 2020 | 11883 | 0.030 |
Why?
|
Ceftriaxone | 1 | 2017 | 175 | 0.030 |
Why?
|
Kinetics | 1 | 2024 | 6328 | 0.030 |
Why?
|
Geography | 1 | 2018 | 652 | 0.030 |
Why?
|
Leukocytosis | 1 | 2017 | 251 | 0.030 |
Why?
|
Cardiomyopathies | 2 | 2020 | 2057 | 0.030 |
Why?
|
Temperature | 1 | 2022 | 2234 | 0.030 |
Why?
|
Vitamin K Deficiency | 1 | 2015 | 24 | 0.030 |
Why?
|
Research Personnel | 1 | 2020 | 589 | 0.030 |
Why?
|
Ventricular Remodeling | 1 | 2023 | 1281 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2021 | 1140 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2009 | 4791 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2227 | 0.030 |
Why?
|
Spinal Puncture | 1 | 2017 | 286 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2121 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20757 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.030 |
Why?
|
Prothrombin | 1 | 2015 | 194 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2018 | 948 | 0.030 |
Why?
|
Glucose Intolerance | 1 | 2019 | 579 | 0.030 |
Why?
|
Comprehension | 1 | 2020 | 639 | 0.030 |
Why?
|
Administration, Sublingual | 1 | 2014 | 60 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2021 | 1070 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2022 | 12464 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2021 | 1429 | 0.030 |
Why?
|
Focus Groups | 1 | 2020 | 1460 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 138 | 0.030 |
Why?
|
Genome | 1 | 2022 | 1754 | 0.030 |
Why?
|
India | 1 | 2020 | 2334 | 0.030 |
Why?
|
Genome, Viral | 1 | 2017 | 674 | 0.030 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 163 | 0.030 |
Why?
|
Interview, Psychological | 1 | 2016 | 811 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2014 | 554 | 0.030 |
Why?
|
Luminescence | 1 | 2013 | 108 | 0.030 |
Why?
|
Nose | 1 | 2017 | 522 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2016 | 664 | 0.030 |
Why?
|
Liver | 1 | 2008 | 7574 | 0.030 |
Why?
|
Isoniazid | 1 | 2014 | 288 | 0.030 |
Why?
|
Rifampin | 1 | 2014 | 352 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2019 | 1341 | 0.020 |
Why?
|
Microbial Viability | 1 | 2013 | 237 | 0.020 |
Why?
|
Weight Loss | 1 | 2024 | 2721 | 0.020 |
Why?
|
Haplotypes | 1 | 2018 | 2722 | 0.020 |
Why?
|
Motivation | 1 | 2021 | 2020 | 0.020 |
Why?
|
Kidney | 1 | 2006 | 7065 | 0.020 |
Why?
|
Family Characteristics | 1 | 2016 | 1003 | 0.020 |
Why?
|
Plasmodium vivax | 1 | 2013 | 203 | 0.020 |
Why?
|
Cross Infection | 1 | 2020 | 1426 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2018 | 2433 | 0.020 |
Why?
|
Drug Utilization | 1 | 2017 | 1190 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2021 | 5902 | 0.020 |
Why?
|
Immunoglobulin A | 1 | 2014 | 991 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3514 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2726 | 0.020 |
Why?
|
Reminder Systems | 1 | 2013 | 388 | 0.020 |
Why?
|
Filtration | 1 | 2010 | 229 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2022 | 4541 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5314 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2014 | 1527 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3476 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2731 | 0.020 |
Why?
|
Health Services Research | 1 | 2017 | 1815 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6517 | 0.020 |
Why?
|
Triclosan | 1 | 2008 | 58 | 0.020 |
Why?
|
Premature Birth | 1 | 2020 | 1829 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4857 | 0.020 |
Why?
|
RNA, Ribosomal, 23S | 1 | 2007 | 54 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2018 | 2235 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2019 | 3573 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3237 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1078 | 0.020 |
Why?
|
Heart | 1 | 2020 | 4444 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4785 | 0.020 |
Why?
|
Mutagenesis, Insertional | 1 | 2008 | 661 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 13000 | 0.020 |
Why?
|
Immunoglobulins | 1 | 2009 | 854 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5799 | 0.020 |
Why?
|
Hematuria | 1 | 2006 | 232 | 0.020 |
Why?
|
RNA, Bacterial | 1 | 2007 | 393 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36742 | 0.010 |
Why?
|
Workload | 1 | 2010 | 849 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3435 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10264 | 0.010 |
Why?
|
DNA Primers | 1 | 2007 | 2827 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2020 | 4884 | 0.010 |
Why?
|
Animals | 3 | 2022 | 169222 | 0.010 |
Why?
|
Gene Deletion | 1 | 2008 | 2673 | 0.010 |
Why?
|
Genetic Variation | 1 | 2016 | 6611 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4576 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7939 | 0.010 |
Why?
|
Algorithms | 1 | 2017 | 14163 | 0.010 |
Why?
|
Biopsy | 1 | 2006 | 6786 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2009 | 17128 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2008 | 22381 | 0.010 |
Why?
|
Mice | 1 | 2008 | 82024 | 0.000 |
Why?
|